Ozempic Hair Loss Risk
Ozempic and Wegovy may raise hair loss risk in some men, study finds
Introduction To Hair Loss And GLP-1 Medications
Men who are genetically predisposed to androgenetic alopecia, the most common type of hair loss, may face an increased risk of losing hair when using medications such as Ozempic, Wegovy, and Zepbound for type 2 diabetes and obesity. A new study conducted by researchers at NYU Langone Health found that these men may have an additional 7 percent risk of hair loss when taking these drugs. The study examined the GLP1R gene, which naturally influences levels of glucagon-like peptide-1 (GLP-1) receptor proteins in the body, and compared genetic patterns associated with GLP1R activity with genes found in men who have androgenetic alopecia.
Understanding The Genetic Connection
The researchers used activity involving the GLP1R gene as an indicator of GLP-1 agonist activity, which is associated with higher levels of GLP-1 receptor proteins. They found that genetic variants associated with naturally higher levels of GLP-1 receptor proteins were more common in men with androgenetic alopecia. Even after adjusting for hypertension, a known risk factor for hair loss, the additional 7 percent risk remained. The study also examined whether other conditions, such as insulin resistance and reduced testosterone levels, might account for the association, but neither factor explained the result.
Real-World Implications And Future Outlook
The findings of this study provide evidence supporting the possibility that genetics play a role in the hair loss associated with GLP-1 medications. The researchers suggest that genetic screening could eventually help doctors identify people who may be especially vulnerable to hair loss before they begin taking these medications. This could lead to the development of combination treatments to prevent hair loss, such as minoxidil or other drugs. However, more research is necessary to determine exactly how GLP-1 activity might interfere with hair follicle growth, and to investigate whether the same genetic connection found in men is present in women.
Current State Of Hair Loss Research
Hair thinning has been reported by both men and women taking GLP-1 drugs, and until now, researchers have generally attributed much of that shedding to rapid weight loss. However, the new findings suggest that there may be an underlying biological connection between GLP-1 use and an increased risk of male-pattern hair loss from androgenetic alopecia. The study's senior investigator, Lynn Petukhova, PhD, noted that the overlapping genetic risk suggests that the two may share an underlying biological connection, and that the findings could eventually help doctors identify people who may be especially vulnerable to hair loss.
Conclusion And Future Research Directions
The study's findings have significant implications for the treatment of type 2 diabetes and obesity, and highlight the need for further research into the genetic connection between GLP-1 use and hair loss. As the use of GLP-1 medications becomes more widespread, it is essential to understand the potential risks and benefits of these drugs, and to develop strategies to mitigate any negative side effects. Future studies will be necessary to determine the exact mechanisms by which GLP-1 activity interferes with hair follicle growth, and to investigate whether genetic screening can be used to identify individuals at high risk of hair loss.
Sources
This is an original synthesis by Qivorane based on reporting from the outlets below.